Ventricular Dysfunction
In PCI for MI, spironolactone does not meet primary endpoints but may show benefit in HF
CHICAGO — In patients with acute MI who underwent PCI, spironolactone did not improve the primary composite outcomes but was linked to reduced risk for new or worsening HF, according to new data from the CLEAR SYNERGY (OASIS-9) trial.
Trial of new driver for pediatric VAD could transform research for children with HF
The first prospective FDA-regulated device trial using a pediatric ventricular assist device registry was launched in November. It could transform how research is conducted in children with advanced heart failure.
Apple Watch app, using AI, identifies left ventricular dysfunction
Applying artificial intelligence to an Apple Watch ECG can reliably and safely identify left ventricular dysfunction in a nonclinical setting, researchers reported in a proof-of-concept study.
Recall of ventricular assist device implant kit designated Class I
The FDA has identified Medtronic’s recall of its ventricular assist device implant kit as Class I recall, the most serious type, due to risk for serious injuries or death.
Cardiac dysfunction from cancer therapies increases risk for pregnancy-related HF
Women who had a history of cardiac dysfunction related to cancer therapeutics had a 47.4-fold increased risk for HF or left ventricular dysfunction during pregnancy or within 12 months after delivery, according to a systematic review.
Risk reduction from AF ablation may be more modest than observed in CASTLE-AF
The benefits of ablation in patients with atrial fibrillation and HF was more modest in clinical practice than reported in the CASTLE-AF trial, according to a study published in HeartRhythm.
Part of the Healio Network
Cardiac Cycle
The cardiac cycle refers to the diastolic and systolic actions of the heart that creates forward blood blow.